CT0590: A Triple-Knockout Allogeneic BCMA CAR T Therapy Advances Treatment in Multiple Myeloma and Plasma Cell Leukemia

MedXY Editorial Team•Sep 11, 2026•Hematology-Oncology

CT0590 is a triple-knockout allogeneic BCMA CAR T-cell therapy designed to overcome host-versus-graft immune reactions, armed with an NKG2A CAR to resist NK cell-mediated killing.
Preclinical studies demonstrated enhanced resistance against host NK cells and robust anti-myeloma activity in vivo.
In a phase 1 first-in-human study involving 5 heavily pretreated patients with relapsed/refractory multiple myeloma and plasma cell leukemia, CT0590 showed a favorable safety profile without graft-versus-host disease (GVHD) or dose-limiting toxicities.
Clinical responses included stringent complete responses with durable remissions beyond 20 months, associated with high universal CAR T-cell expansion and elevated baseline NKG2A expression on NK cells in responders.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

CT0590 is a triple-knockout allogeneic BCMA CAR T-cell therapy designed to overcome host-versus-graft immune reactions, armed with an NKG2A CAR to resist NK cell-mediated killing.
Preclinical studies demonstrated enhanced resistance against host NK cells and robust anti-myeloma activity in vivo.
In a phase 1 first-in-human study involving 5 heavily pretreated patients with relapsed/refractory multiple myeloma and plasma cell leukemia, CT0590 showed a favorable safety profile without graft-versus-host disease (GVHD) or dose-limiting toxicities.
Clinical responses included stringent complete responses with durable remissions beyond 20 months, associated with high universal CAR T-cell expansion and elevated baseline NKG2A expression on NK cells in responders.